We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Industry Wants to See eCTD Benefit at FDA, Expert Says

Industry Wants to See eCTD Benefit at FDA, Expert Says

January 31, 2006

Adoption of the electronic common technical document (eCTD) is growing quickly as firms recognize that it makes their lives easier to file something once for different regulatory bodies, but industry may not fully embrace the technology until it is convinced that it will speed esubmissions to the FDA, expert Kim Nitahara told PIR last week.

“There’s an enormous interest globally in eCTD,” said Nitahara, a long-time leader in the field and CEO of Meta Solutions. Larger companies are adopting it more quickly than smaller firms with fewer financial and personnel resources, he noted, but even companies that focus on one region of the globe are finding it valuable because many drugs and devices are sold worldwide today. “But if industry doesn’t see the benefit of using eCTD at the FDA,” it won’t move so quickly to adopt it, Nitahara said.

The agency recognizes this, and that’s a big part of the recent push it has made at public forums advocating eCTD and esubmissions, he noted. For example, Nitahara will be hosting a Drug Information Association summit in Philadelphia next month where FDA officials will discuss in greater detail how regulated firms are using eCTD and how they can work more effectively with the agency to ramp up efforts in that direction.

Nitahara hopes agency officials will also provide more details about its imminent revision of 21 CFR Part 11 at the Philadelphia gathering. However, sources close to the agency have told PIR that the revised Part 11 may not go public until April. “It’s going slower internally than the agency had expected,” one consultant said FDA officials told her.

Meanwhile, the FDA is intent on helping firms improve their eCTD efforts and demonstrate that the agency – and all of its reviewers – is actively encouraging its use. At a recent CDER online Town Hall meeting, FDA staff expressed some surprise when told by several questioners that they had felt some resistance to the format from their individual inspector.

“I’m not sure how much advantage industry is seeing from the FDA [right now] in terms of speed or quality of review” when using eCTD versus paper, Nitahara noted. — Michael Causey

KEYWORDS esubmission FDA

    Upcoming Events

    • 28Sep

      The Cost of Counterfeiting: Why You Need a Plan to Secure Your Medical Device Supply Chain

    • 28Sep

      Calculating Sample Size to Satisfy FDA Expectations

    • 11Oct

      GMP Quality Management vSummit 2023: Where Quality Meets Risk

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    • 08Nov

      18th Annual FDA Inspections vSummit

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Manufacturing Cost is Key Issue Facing Gene Therapy Products, Marks Says

    • Artificial Womb Technology Not Yet Ready for Human Trials Adcomm Says

    • Top Concern for CBER is Marketing of Unapproved Biologics, Says FDA Official

    • FDA Deems Medline Industries’ Saline Solution Vial Recall as Class 1

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing